Company: NCEL
Filing Date: 2025-09-03
Form Type: F-4/A
Source: 0001213900-25-084157
Chunk: 785

Company: NewcelX Ltd.
Filing Date: 2025-09-03
Form: F-4/A
Chunk 785
---
 2024 |     |   |      2023 |
|:---------------------------------------|:----|:-------------|--------:|:----|:--|----------:|
| Professional consultants’ expenses     |     | $            | 110,345 |     | $ |   332,690 |
| Vendor liabilities                     |     |              |       — |     |   |   112,635 |
| Stamp tax                              |     |              | 125,793 |     |   |         — |
| Related party interest short term loan |     |              |       — |     |   |    25,605 |
| Accrued Board of Directors fees        |     |              |  47,586 |     |   |   184,672 |
| Accrued bonus                          |     |              |       — |     |   |   960,025 |
| Other accrued expenses                 |     |              |  27,554 |     |   |    36,643 |
| Total other accrued liabilities        |     | $            | 311,278 |     | $ | 1,652,270 |

Note 7 Deferred Revenues: In February 2019, the Company entered into the EF License Agreement, to develop and commercialize its product candidate, Nolazol, in Latin American countries with Eurofarma Laboratorios S.A., a Brazilian pharmaceutical company. The EF License Agreement covered the grant of non -transferablelicenses, without the right to sublicense, to Eurofarma to develop and commercialize Nolazol in Latin America. The EF License Agreement also specified the Company’s obligation to advance ongoing development activities with respect to Nolazol in the United States. A joint steering committee oversaw the development and regulatory activities directed towards marketing approval, manufacturing and commercialization phases. The Company believed its participation in the joint steering committee was not of material significance to the licenses in the context of the EF License Agreement on the whole and, as such, management excluded these activities in the determination of its performance obligation(s) under the EF License Agreement. The EF License Agreement provided that the parties would enter into a separate manufacturing and supply agreement during the term of the EF License Agreement. Under the EF License Agreement, the Company received a non -refundable, upfront payment, of $ 2.5million and was further eligible to receive non -refundablemilestone payments of up to $ 16million, based on the achievement of milestones related